C WorldWide Group Holding A S reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 9.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 110,240 shares of the medical device company’s stock after selling 11,709 shares during the period. DexCom makes up about 0.2% of C WorldWide Group Holding A S’s investment portfolio, making the stock its 28th biggest position. C WorldWide Group Holding A S owned approximately 0.12% of DexCom worth $16,452,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in DXCM. Gradient Investments LLC acquired a new position in DexCom in the second quarter valued at approximately $25,000. Virtus ETF Advisers LLC acquired a new position in DexCom in the second quarter valued at approximately $29,000. Steward Partners Investment Advisory LLC acquired a new position in DexCom in the second quarter valued at approximately $31,000. CSat Investment Advisory L.P. acquired a new position in DexCom in the second quarter valued at approximately $31,000. Finally, Wealthcare Advisory Partners LLC acquired a new position in DexCom in the second quarter valued at approximately $37,000. Institutional investors and hedge funds own 96.19% of the company’s stock.
DXCM has been the topic of several analyst reports. Canaccord Genuity increased their target price on shares of DexCom from $185.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday. BTIG Research reiterated a “hold” rating on shares of DexCom in a report on Thursday, August 1st. Raymond James increased their target price on shares of DexCom from $172.00 to $189.00 and gave the stock an “outperform” rating in a report on Thursday. Oppenheimer increased their target price on shares of DexCom from $180.00 to $205.00 in a report on Thursday. Finally, Morgan Stanley increased their target price on shares of DexCom from $175.00 to $202.00 and gave the stock an “equal weight” rating in a report on Thursday. Five research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. DexCom currently has an average rating of “Buy” and an average price target of $190.67.
In related news, insider Andrew K. Balo sold 9,107 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $151.56, for a total value of $1,380,256.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nicholas Augustinos sold 1,208 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $145.49, for a total transaction of $175,751.92. The disclosure for this sale can be found here. Insiders have sold 104,014 shares of company stock valued at $16,183,576 in the last three months. 1.80% of the stock is owned by insiders.
Shares of DXCM stock traded up $3.38 during trading hours on Friday, hitting $198.08. 2,579,085 shares of the company were exchanged, compared to its average volume of 1,138,477. The business has a 50 day moving average of $154.75 and a two-hundred day moving average of $145.88. The company has a current ratio of 6.05, a quick ratio of 5.64 and a debt-to-equity ratio of 1.56. DexCom, Inc. has a 52 week low of $105.05 and a 52 week high of $200.80. The company has a market capitalization of $14.00 billion, a PE ratio of 660.27 and a beta of 0.64.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, November 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.45. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The company had revenue of $396.30 million during the quarter, compared to the consensus estimate of $348.99 million. During the same quarter in the prior year, the firm earned $0.17 earnings per share. The firm’s revenue was up 48.6% compared to the same quarter last year. On average, research analysts forecast that DexCom, Inc. will post 0.94 EPS for the current year.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Elliott Wave Theory
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.